# US 2023/0272109 A1 · Anti-claudin 18.2 antibody and antibody-drug conjugate thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272109 A1
- Document ID: US20230272109A1
- Status: Published application
- Kind: A1
- Application number: 18/016,352
- Filed: 2022-05-07
- Published: 2023-08-31
- Earliest claimed: 2021-05-08
- Assignees: Remegen Co., Ltd.
- Applicants: Remegen Co., Ltd.
- Inventors: Jianmin FANG; Yuanhao LI; Marie M. ZHU; Jing JIANG; Yuelei SHEN; Shenjun LI; Wenting LUO; Xiaoping ZHANG; Lili WANG; Ling WANG; Qinbin ZHANG; Fang YANG
- Web page: https://patentgrep.com/patent/US20230272109A1

## CPC

- C07K 16/30: from tumour cells
- A61K 31/351: not condensed with another ring
- A61K 31/381: having five-membered rings
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 47/6801: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are an antibody targeting Claudin 18.2, an antibody-drug conjugate, and use thereof in treatment of cancer. Also provided are a nucleotide encoding the Claudin 18.2 antibody, a polynucleotide combination, an expression vector, an expression vector combination, a pharmaceutical composition comprising the Caudill 18.2 antibody and the antibody-drug conjugate, and an application thereof in preparation of a medication for treatment or prevention of cancer.

## Claims

### Claim 1

An anti-Claudin 18.2 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, and the heavy chain variable region and/or the light chain variable region has a CDR sequence identical to that of an antibody defined by the following sequences or obtained by 1-2 amino acid substitutions of the CDR of the antibody defined by the following sequences:
(1) an amino acid sequence of a heavy chain variable region as shown in SEQ ID NO: 1; and/or
(2) an amino acid sequence of a light chain variable region as shown in SEQ ID NO: 2.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, and:
(1) for the heavy chain variable region, CDR1 has an amino acid sequence as shown in SEQ ID NO: 3, 4, 5, 6 or 7 or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 3, 4, 5, 6 or 7; CDR2 has an amino acid sequence as shown in SEQ ID NO: 8, 9, 10, 11 or 12, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 8, 9, 10, 11 or 12; CDR3 has an amino acid sequence as shown in SEQ ID NO: 13, 14, 15, 16 or 17, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 13, 14, 15, 16 or 17;
(2) for the light chain variable region, CDR1 has an amino acid sequence as shown in SEQ ID NO: 18, 19, 20, 21 or 22 or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 18, 19, 20, 21 or 22; CDR2 has an amino acid sequence as shown in SEQ ID NO: 23, 24, 25, 26 or 27, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 23, 24, 25, 26 or 27; CDR3 has an amino acid sequence as shown in SEQ ID NO: 28, 29, 30, 31 or 32, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 28, 29, 30, 31 or 32.

### Claim 3 (depends on 2)

The antibody or antigen-binding fragment thereof according to claim 2, and,
(1) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 3, 8 and 13 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 3, 8 and 13, and/or the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 18, 23 and 28 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 18, 23 and 28;
(2) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 4, 9 and 14 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 4, 9 and 14, and/or the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 19, 24 and 29 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 19, 24 and 29;
(3) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 5, 10 and 15 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 5, 10 and 15, and/or the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 20, 25 and 30 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 20, 25 and 30;
(4) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 6, 11 and 16 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 6, 11 and 16, and/or the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 21, 26 and 31 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 21, 26 and 31;
(5) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 7, 12 and 17 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 7, 12 and 17, and/or the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 22, 27 and 32 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 22, 27 and 32.

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, and:
(1) the heavy chain variable region has an amino acid sequence as shown in SEQ ID NO: 1, or comprises the same CDRs 1-3 as in SEQ ID NO: 1 and more than 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1; and/or
(2) the light chain variable region has an amino acid sequence as shown in SEQ ID NO: 2, or comprises the same CDRs 1-3 as in SEQ ID NO: 2 and more than 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2;
(1) the heavy chain has an amino acid sequence as shown in SEQ ID NO: 33; and/or
(2) the light chain has an amino acid sequence as shown in SEQ ID NO: 34.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof includes a monoclonal antibody, Fab, Fab′, Fab′-SH, F(ab′)2, Fv, single chain Fv (scFv), bispecific antibody, multispecific antibody, chimeric antibody, humanized antibody or fusion protein comprising an antigen-binding fragment of an antibody; the antibody is a humanized monoclonal antibody.

### Claim 7 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, further comprising a human or murine constant region; the constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

### Claim 8 (depends on 1)

An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to claim 1.

### Claim 9 (depends on 1, 8)

The antibody-drug conjugate according to claim 8, wherein the antibody-drug conjugate has a structure represented by formula (I):
Ab-L-D (I)
wherein:
Ab is the antibody or antigen-binding fragment thereof according to claim 1;
D is an active drug unit;
L is any linking group, which is covalently linked to the antibody or antigen-binding fragment thereof Ab and the active drug unit D, respectively;
wherein, Ab is linked to one or more active drug units D through one or more linking groups L.

### Claim 10 (depends on 9)

The antibody-drug conjugate according to claim 9, wherein L is covalently linked to an amino residue or a thiol residue of the antibody Ab; may be L is covalently linked to a thiol residue of the antibody Ab; may be, L is covalently linked to a thiol residue formed by breaking an interchain disulfide bond of the antibody Ab.

### Claim 11 (depends on 9)

The antibody-drug conjugate according to claim 9, wherein L includes a cleavable linker and a non-cleavable linker;
the cleavable linker includes a peptide unit comprising 2 to 20 amino acids, the peptide linker is selected from the group consisting of -valine-citrulline- (-Val-Cit-), -glycine-glycine-phenylalanine-glycine- (-Gly-Gly-Phe-Gly-), -valine-alanine- (-Val-Ala-), -valine-lysine- (-Val-Lys-), -valine-arginine- (-Val-Arg-), -phenylalanine-citrulline- (-Phe-Cit-), -phenylalanine-lysine- (-Phe-Lys-), -phenylalanine-arginine- (-Phe-Arg-) and a combination thereof.

### Claim 12

(canceled)

### Claim 13 (depends on 9)

The antibody-drug conjugate according to claim 9, wherein L comprises a structure selected from the group consisting of:

### Claim 14 (depends on 9)

The antibody-drug conjugate according to claim 9, wherein the active drug unit D is selected from the group consisting of a cytotoxic molecule, cell differentiation factor, stem cell trophic factor, steroid drug, drug for the treatment of autoimmune diseases, anti-inflammatory drug, and drug for the treatment of infectious diseases; the cytotoxic molecule includes but is not limited to a tubulin inhibitor or a DNA damaging agent; the tubulin inhibitor includes but is not limited to a cytotoxic molecule of dolastatins and auristatins, a cytotoxic molecule of maytansines; the DNA damaging agent includes but is not limited to calicheamicins, duocarmycins, anthramycin derivative pyrrolobenzodiazepine (PBD), camptothecins and a derivative thereof, and SN-38; more the cytokine molecule of auristatins includes but is not limited to MMAE, MMAF, or a derivative thereof; and the cytotoxic molecule of maytansines includes but is not limited to DM1, DM4, or a derivative thereof.

### Claim 15 (depends on 9)

The antibody-drug conjugate according to claim 9, wherein the active drug unit D has a structure selected from the group consisting of:

### Claim 16 (depends on 9)

The antibody-drug conjugate according to claim 9, wherein the antibody-drug conjugate has a structure selected from the group consisting of:
wherein, p is an integer selected from 1, 2, 3, 4, 5, 6, 7, and 8, and q is an integer selected from 1, 2, 3, and 4.

### Claim 17 (depends on 1)

An isolated polynucleotide or combination thereof, encoding the antibody or antigen-binding fragment thereof according to claim 1.

### Claim 18 (depends on 17)

A nucleic acid construct comprising the polynucleotide according to claim 17, wherein the nucleic acid construct is a vector.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

A host cell comprising the nucleic acid construct according to claim 18, wherein the cell is selected from the group consisting of a prokaryotic cell, eukaryotic cell, yeast cell, mammalian cell, E. coli cell or CHO cell, NS0 cell, Sp2/0 cell, and BHK cell.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 20)

A method for producing an anti-Claudin 18.2 antibody, comprising culturing the host cell according to claim 20 under a condition suitable for expressing a vector encoding an anti-Claudin 18.2 antibody or an antigen-binding fragment thereof, and recovering the antibody or fragment.

### Claim 24 (depends on 1)

A method for treating or preventing cancer, comprising administering the antibody or antigen-binding fragment thereof according to claim 1 to a subject in need thereof,
the cancer is a solid tumor; further, the solid tumor includes gastric cancer and pancreatic cancer.

### Claim 25

(canceled)
